Diadem Precision Technologies

Diadem Biotherapeutics is a private U.S. biotechnology company developing engineered extracellular vesicle therapeutics for cancer, autoimmune, and chronic inflammatory diseases. The company positions itself as a platform therapeutics business that uses bioengineering, immunology, and multi-omics to design exosome-like vesicles that mimic cell-to-cell communication and modulate immune responses. Its core platform, DECOSTAR, is intended to overcome limitations of conventional biologics in agonist signaling and enable access to immunotherapy targets that may be difficult to drug with standard antibodies. Public information indicates the company remains preclinical, with a broad but largely undisclosed pipeline rather than named clinical assets. Diadem has participated in the BioLabs LA ecosystem and received an Amgen Golden Ticket, underscoring its position as an emerging early-stage immunotherapy company.